What is precision oncology?

An approach to cancer treatment that matches therapies to the specific molecular alterations found in a patient’s tumor, typically identified through genomic sequencing. A 2025 study found molecular-matched treatment independently associated with improved outcomes even for genomic alterations with weaker supporting evidence than the most established tier, though genetic matching alone does not explain all variation in treatment response.

How does spatial profiling support precision medicine?

By revealing where in a tumor a genetic alteration sits and what microenvironmental context surrounds it, information a standard genomic report cannot capture. A 2024 study found genetically identical tumor subclones showing different predicted drug sensitivity depending purely on their location within the tumor, demonstrating that microenvironmental context, not just genetic identity, shapes treatment response.

Can spatial data guide therapy selection?

Increasingly, yes. Spatial profiling can reveal a sensitivity gradient across different regions of the same tumor, meaning a single-biopsy genomic report may not represent the tumor’s full therapeutic landscape. Molecular tumor boards, which already require understanding each genetic alteration’s contextual functional effects, are a natural setting for incorporating this kind of spatial context into treatment decisions.

Precision oncology and spatial profiling

Highlights in this article

Precision oncology beyond mutations
What spatial adds to molecular profiling
Spatial context in therapy selection
Molecular tumor boards
Barriers to adoption

Practicing precision oncology has meant, for most of the field’s history, matching a tumor’s specific genetic alterations to a therapy designed against that alteration. That approach has genuinely improved outcomes, and it has a real, if partial, evidence base behind it. It has not solved treatment failure, and a growing body of spatial evidence increasingly points to why: the genetic match itself can be entirely correct while the tumor’s microenvironmental context determines whether that match actually translates into a drug working.


Key takeaways Molecular-matched treatment for weaker-tier genomic alterations was independently associated with improved outcome in a 2025 study of 1,230 patients, confirming real value in the mutation-based paradigm even beyond the strongest evidence tier. A 2024 study found genetically identical tumor subclones showing different drug sensitivity depending purely on their physical location within the tumor, with a sensitivity gradient running from tumor core to periphery. That finding rules out genetic heterogeneity as the explanation for the observed variability, since the subclones were genetically identical, leaving microenvironmental position as the operative variable. Molecular tumor boards already require understanding each genetic alteration’s contextual functional effects, which spatial data can supply directly rather than leaving to inference. Turnaround time, cost and the absence of standardized reporting formats remain real barriers to routinely incorporating spatial data into today’s tumor board workflow.

Key takeaways

Molecular-matched treatment for weaker-tier genomic alterations was independently associated with improved outcome in a 2025 study of 1,230 patients, confirming real value in the mutation-based paradigm even beyond the strongest evidence tier.
A 2024 study found genetically identical tumor subclones showing different drug sensitivity depending purely on their physical location within the tumor, with a sensitivity gradient running from tumor core to periphery.
That finding rules out genetic heterogeneity as the explanation for the observed variability, since the subclones were genetically identical, leaving microenvironmental position as the operative variable.
Molecular tumor boards already require understanding each genetic alteration’s contextual functional effects, which spatial data can supply directly rather than leaving to inference.
Turnaround time, cost and the absence of standardized reporting formats remain real barriers to routinely incorporating spatial data into today’s tumor board workflow.

Precision oncology beyond mutations

The mutation-matching paradigm has a genuine evidence base, and it is worth stating that evidence fairly before describing its limits. A 2025 study analyzing next-generation sequencing data from 1,230 advanced cancer patients presented at an institutional molecular tumor board examined outcomes for patients whose treatment matched genomic alterations classified at ESCAT tier II or III, alterations with meaningfully weaker supporting evidence than the strongest, tier I alterations. In multivariable analysis, the molecular-matched approach was independently associated with improved outcome, with a hazard ratio of 0.50. That is a real, quantified benefit extending mutation matching’s value beyond only the most established genetic alterations.

That real value is exactly why the paradigm’s limits matter, rather than undermining the case for precision oncology generally. A correct genetic match is necessary for a targeted therapy to have any chance of working, but the evidence increasingly shows it is not sufficient, and the missing piece is frequently spatial: not a different mutation, but a different physical context surrounding an identical one.

What spatial adds to molecular profiling

The clearest available demonstration of this comes from breast cancer, a disease whose precision oncology paradigm, built around estrogen receptor, progesterone receptor, and HER2 status, is among the most established in all of oncology.


The same genetic subclone, two different drug responses A 2024 study, now peer-reviewed in NAR Cancer, acquired spatial transcriptomics data from 9 breast cancer patients spanning luminal, HER2-positive, and triple-negative subtypes, and used a computational tool called Beyondcell to predict sensitivity to more than 1,200 drugs while explicitly accounting for spatial context and the interaction between tumor and microenvironment compartments. The study found diverse response patterns across tumor, interphase, and microenvironment regions, revealing a sensitivity and functional gradient running from the tumor core to its periphery. The most direct finding for precision oncology specifically: the study identified genetically identical subclones with different predicted drug responses depending on their location within the tumor ducts. Because the subclones were genetically identical, genetic heterogeneity cannot explain the difference in predicted response. The tumor’s spatial and microenvironmental context can. That is a precise, mechanistic answer to why two patients, or even two regions of the same patient’s tumor, with the identical actionable mutation can respond differently to the therapy matched against it.

The same genetic subclone, two different drug responses

A 2024 study, now peer-reviewed in NAR Cancer, acquired spatial transcriptomics data from 9 breast cancer patients spanning luminal, HER2-positive, and triple-negative subtypes, and used a computational tool called Beyondcell to predict sensitivity to more than 1,200 drugs while explicitly accounting for spatial context and the interaction between tumor and microenvironment compartments. The study found diverse response patterns across tumor, interphase, and microenvironment regions, revealing a sensitivity and functional gradient running from the tumor core to its periphery.

The most direct finding for precision oncology specifically: the study identified genetically identical subclones with different predicted drug responses depending on their location within the tumor ducts. Because the subclones were genetically identical, genetic heterogeneity cannot explain the difference in predicted response. The tumor’s spatial and microenvironmental context can. That is a precise, mechanistic answer to why two patients, or even two regions of the same patient’s tumor, with the identical actionable mutation can respond differently to the therapy matched against it.

Spatial context in therapy selection

The practical implication of a core-to-periphery sensitivity gradient existing within a single tumor is not that mutation-based matching should be abandoned, but that a single genomic report, sampling one region of a tumor, may not represent the therapeutic vulnerability of the tumor as a whole.

A genomic panel run on a single biopsy core reports the genetic alterations present in that specific piece of tissue. If a tumor’s drug sensitivity genuinely varies with position, as the breast cancer study demonstrates, a therapy selected purely from that single-region report is being matched against only part of the tumor’s actual therapeutic landscape, a limitation no amount of additional genomic depth at that same location can correct, since the missing information is about a different location entirely, not a more thorough reading of the same one.

Molecular tumor boards

Molecular tumor boards are the clinical setting where this gap between genetic matching and microenvironmental reality is most directly relevant, since they are the mechanism by which a patient’s molecular profile actually becomes a treatment decision.

These boards are defined as panels of expert physicians, scientists, health care providers, and patient advocates who review and interpret molecular profiling results for individual patients and match them to available therapies, including investigational drugs. Critically, that interpretive task is described as requiring an understanding of each alteration’s contextual functional effects and its correlation with treatment sensitivity or resistance, not simply whether the alteration is present. Spatial data is a direct, measurable source of exactly that context, rather than something a tumor board currently has to infer from general knowledge about a gene’s typical behavior.

That reframes what a genuinely complete molecular tumor board input could look like: not only a genomic report listing detected alterations, but a spatial map showing where in the tumor each alteration-bearing region sits and what microenvironmental context surrounds it, giving the board a more direct basis for the contextual judgment its own definition already says it requires.

Barriers to adoption

Despite the clarity of the underlying rationale, incorporating spatial data into routine molecular tumor board practice faces real, practical barriers that a precision oncology program should plan around rather than assume away.

Turnaround time competes with clinical urgency. A molecular tumor board decision for an advanced cancer patient often needs to happen quickly, and a spatial profiling workflow layered onto an already-running genomic panel adds time a board may not have.
Cost and reimbursement remain unresolved for an additional, non-standard test. A genomic panel has an established reimbursement pathway in most settings; a spatial assay run specifically to inform a tumor board discussion generally does not yet have an equivalent, established coverage pathway.
No standardized reporting format yet exists for tumor boards to consume spatial data the way they already consume a genomic variant report. A tumor board is built around interpreting a familiar report format; spatial data, without an equivalent standardized summary, requires a different kind of expertise to interpret in real time during a board discussion.

How a spatial biomarker moves toward the kind of trial-ready, prospectively usable signature this article’s barriers point toward is covered from the clinical development side in Predictive Spatial Signatures for Patient Stratification, and the broader clinical translation and workflow questions this raises are addressed in Translating Spatial Biology Into the Clinic: Digital Pathology and Beyond.

For the regulatory and assay development path a spatial biomarker follows toward routine clinical use, see Spatial Biomarkers and Companion Diagnostics: The Next Frontier, and for where precision oncology sits within the full spatial biology pipeline, Spatial Biology in Drug Discovery: From Target Discovery to Translational Medicine.

This article was produced under Drug Discovery News’s AI editorial policies.